Shows / The Top Line

The Top Line
Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning.
The show, from its episodes
No episode notes yet. Recurring topics, people and starter picks will appear when notes are available.
Typical episode length
19m · median of 129 episodes with a known length
Solo / guest format
Unknown — existing notes name people mentioned, but do not identify hosts or guests.
Recurring topics
No recurring topics established yet.
Recurring people
No recurring people established yet.
Start here
No starter picks yet — no published episodes with audio and a recorded notes hook.
Episodes
The Top LinePatent expirations push biopharma industry toward a tougher 2026
In this week’s episode of “The Top Line,” we take a deep dive into the fourth-quarter performance of the biopharma industry and how the…
The Top LineAs AI evolves, the modern R&D lab is changing
The design of the modern R&D lab may be due for a rethink. Artificial intelligence and automation are reshaping how science gets done, yet many of the physical…
The Top LineHow physiology powers biotech innovation (Sponsored)
Physiology connects genes and molecules to whole-body function, shaping every stage of drug discovery and development. In this sponsored episode of The Top…
The Top LineAutoimmune CAR-T: Navigating the FDA’s new regulatory playbook
For more than a decade, CAR-T therapy has been the miracle of oncology, turning end-stage blood cancers into curable diseases. But the application of these…
The Top LineInside the sterile fill capacity crunch (Sponsored)
What does the future hold for sterile fill-finish CDMOs in a rapidly evolving market? In this sponsored episode of The Top Line, Denis Johnson, CEO of Grand…
The Top LineTrump's tariff threats, measured by manufacturing
Though uncertainty still surrounds the Trump administration’s pharmaceutical import tariffs, the trade rhetoric set off a clear response across the…
The Top LineWhy patient access must keep pace with drug innovation (Sponsored)
Biopharmaceutical innovation is advancing at an unprecedented pace, yet many patients still face barriers to accessing new medicines. In this episode of Health…
The Top LineWhat were the biggest clinical trial flops of 2025?
Every clinical setback carries lessons. That’s why Fierce revisits major trial failures each year: not to dwell on disappointment, but to understand what…
The Top LineCommunity oncology’s growing role in the future of cancer care (Sponsored)
Community oncology is playing an increasingly important role in how cancer care is delivered across the United States, with a growing share of patients treated…
The Top LineThe biggest potential drug launches of 2026
The leaders of this year’s list of the most anticipated drug launches will likely come as no surprise: Fierce’s annual report on the biggest…
The Top LineHow Mirum is Advancing Rare Disease Care Through Strategic M&A (Sponsored)
Please see the following USPI, US ISI, EU SmPC and Canadian Product Monograph for complete LIVMARLI product information: US Important Safety Information…
The Top LineWhy human expertise still matters in AI-driven med comms (Sponsored)
Artificial intelligence is reshaping medical communications, but it is not a substitute for human judgment. In this episode of The Top Line, experts from RTI…
The Top LineBiopharma's rebound keeping pace so far
In this week’s episode of “The Top Line,” Fierce checks in with professional services juggernaut KPMG on the biopharma rebound many industry…
The Top LineJPM26: Sunshine, AI and the deals that weren't
With this year’s iteration of the J.P. Morgan Healthcare Conference in the rearview mirror, the biopharma industry has officially closed the door on 2025…
The Top LineFrom approval to value: Why evidence storytelling now matters (Sponsored)
As payers focus on long-term outcomes and real-world performance, value matters more than ever. RTI Health Solutions experts discuss how clear evidence…
The Top LineDrug approvals went from crawl to sprint in 2025
In early 2025, the FDA was rocked by sweeping layoffs and leadership turnover, raising questions about whether the agency could maintain its pace in reviewing…
The Top LinePutting patients first: from buzzword to business imperative (Sponsored)
What does it really mean to put patients first in today’s life sciences landscape? In this sponsored episode of The Top Line, leaders from RTI Health…
The Top LineBeyond the AI hype: How life sciences can turn agents into a competitive advantage (Sponsored)
As artificial intelligence continues to dominate conversations across life sciences, many companies are reaching an inflection point between experimentation…
The Top LineChina’s biotech moment goes global, Zai Lab exec says (Sponsored)
China has moved from a fast-following biotech market to a source of globally competitive innovation, according to Josh Smiley, president and chief operating…
The Top LineBiopharma CEOs assess the road ahead in 2026
After a turbulent 2025, the biopharma industry is heading into the new year with major questions still unresolved. A tough biotech investing environment…
The Top LineA year in review and what 2026 holds for biopharma and healthcare
As 2025 closes, biopharma and healthcare are learning to live on shifting ground. In this special year-end episode of "The Top Line," Fierce reporters take…
The Top LineFrom data to decisions: how Walgreens is powering smarter pharma strategies (Sponsored)
Walgreens is emerging as a real-world evidence partner for the biopharma industry, according to a new episode of The Top Line, sponsored by Walgreens. In the…
The Top LineThe biopharma dealmaking landscape and what to expect in 2026
Uncertainty reigned early this year with the inauguration of President Donald Trump and his threats to impose tariffs and slash prescription drug prices. But…
The Top LineAdvocacy, access and the future of cancer care take center stage in new Health Matters episode (Sponsored)
In this episode of Health Matters, GCI Health’s Ryan Kuresman and Health@WPP’s Wendy Lund explore the fast-shifting landscape of cancer care with…
The Top Line2025’s Fiercest Women in Life Sciences are changing the game
Research shows that women remain woefully underrepresented at the highest levels of leadership in the life sciences industry. Those who have broken through…
The Top LineBayer’s collaborative model: Breaking silos to accelerate impact (Sponsored)
Bayer is reshaping its pharmaceutical business with a new operating model designed to enhance collaboration and bring research & development and…
The Top LineInside Foresight’s mission to redefine cancer monitoring (Sponsored)
In this episode of The Top Line, Fierce’s Chris Hayden speaks with Foresight Diagnostics co-founders Dr. Jake Chabon and Dr. Max Diehn about how their…
The Top LineBiopharma industry gathers momentum in Q3
In this week’s episode of "The Top Line," we take a deep dive into the top-line performance of the biopharma industry in the third quarter. After a slow…
The Top LinePreCheck pulse check: What the industry is saying about FDA’s production initiative
As the prospect of import tariffs and drug price reform marshals billions of biopharma investment dollars into the U.S., the feasibility of rapid domestic…
The Top LineHow Pharma Can Build Trust and Reach Patients in Health Marketplaces (Sponsored)
The healthcare marketing landscape is evolving fast — shaped by regulatory shifts, patient empowerment, and the rise of digital health marketplaces. In…
The Top LineBiotech Graveyard
Welcome to the Fierce Biotech Graveyard, our annual ritual remembering the biotechs we lost in 2025 and those on the brink. In this episode, Fierce…
The Top LineFierce 15: Where are they now?
This week's episode of "The Top Line" features a discussion about what’s working now in biotech and what isn't. Recorded Oct. 7 at Fierce Biotech Week…
The Top LineSalesforce’s Mark Sullivan: AI and agentic systems will redefine life sciences (Sponsored)
Life sciences organizations are facing both intense pressure and extraordinary opportunity, according to Mark Sullivan, president of regulated industries at…
The Top LineUnpacking the FDA transparency push on CRLs
The FDA made waves in early September when it announced a plan to publicly release complete response letters (CRLs) at the same time they are issued to…
The Top LineHow Boehringer Ingelheim is buttressing its US business
With a new president of U.S. pharma at the helm—and two key FDA approvals now in the books—Boehringer Ingelheim is sharpening its focus on the…
The Top LineAI is changing drug safety, but governance sets the guardrails (Sponsored)
Artificial intelligence is reshaping drug safety, but governance is just as critical as innovation, according to Marie Flanagan of IQVIA Safety Technologies…
The Top LineA whirlwind week for pharma
Tariffs, drug pricing reform, a government shutdown and a major turnover at one of the world’s largest drugmakers all converged this week, leaving plenty…
The Top LineFierce Biotech's Fierce 15
Despite a challenging year, the biotech industry has continued to push boundaries, taking bold risks in pursuit of groundbreaking science. If anything, this…
The Top LineRebuilding trust in pharma in the age of misinformation
Trust in pharma has always been fragile, and the rise of misinformation has made it even more precarious. In this episode of "The Top Line," recorded at Fierce…
The Top LineSchrödinger taps AI to speed drug discovery (Sponsored)
Robert Abel, chief scientific officer at Schrödinger, says advanced computational tools are changing the pace and accuracy of drug discovery. In a recent…
The Top LineInside the commercial growing pains of hemophilia gene therapies
With Pfizer discontinuing Beqvez and BioMarin scaling back the commercial focus of Roctavian, the curative promise of hemophilia gene therapies is tempered by…
The Top LineA rare kind of leadership, 30 years in the making
Hope, when applied with purpose and action, can be a powerful force for driving change in healthcare. That’s the philosophy of Eugene Woods, CEO of…
The Top LineFormer FDA Chief Scott Gottlieb talks drug pricing, access and innovation (Sponsored)
In the latest episode of the Health Matters podcast, former Food and Drug Administration Commissioner Scott Gottlieb joins WPP’s Wendy Lund, GCI…
The Top LineBig Pharma bounces back in Q2
After many U.S. biopharma companies posted sales declines in the first quarter, the domestic pharma industry largely bounced back to growth in the second…
The Top LineThe battle of the obesity drug heavyweights
While it’s been easy to grow a bit desensitized to the seemingly unstoppable sales growth of Novo Nordisk and Eli Lilly’s GLP-1s quarter after…
The Top LineIs Trump’s MFN pricing order more bark than bite?
Following a barrage of letters from President Donald Trump urging 17 large pharmaceutical companies to implement Most Favored Nation drug pricing reforms in…
The Top LineRebuilding trust: compassionate communication and public health (Sponsored)
In the latest episode of Health Matters, vaccine expert Dr. Paul Offit joins host Wendy Lund to discuss the growing crisis of vaccine hesitancy and what can be…
The Top LineUntangling Sarepta’s gene therapy fallout and a growing trust deficit
Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy Elevidys and growing scrutiny over the…
The Top LineMaking sense of China’s R&D ascent
With an uptick in licensing deals and promising data emerging from China-based biopharmas, especially in oncology, it’s clear the country is poised to…
The Top LineAI, mentorship and finding your voice in pharma marketing
In this episode of "The Top Line," Ayla Ellison, Editor-in-Chief of Fierce Life Sciences and Healthcare, sits down with two longtime industry leaders to talk…
The Top LineBiopharma layoffs aren't letting up
Layoffs in biopharma show no signs of slowing, with workforce reductions holding steady across the first two quarters of 2025. In this week’s episode of…
The Top LinePeter Pitts talks FDA direction, industry communication (Sponsored)
In the latest episode of the Health Matters podcast, Wendy Lund sits down with Peter Pitts, former FDA associate commissioner and current president of the…
The Top LineTeva’s CEO shares ‘Pivot to Growth’ progress
Two and a half years into his tenure as Teva’s CEO, Richard Francis is breaking down the strategy that’s powered the company through nine…
The Top LineAbbVie, ADCs and the future of cancer care
Antibody drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, like many of its peers, has…
The Top LineInside Fierce Medtech's Fierce 15
Every year, the Fierce Medtech team highlights 15 standout companies that are pushing the boundaries of innovation in medical technology. From reinventing…
The Top LineInside ASCO 2025: Big data drops and a towering campaign
Each year, the American Society of Clinical Oncology annual meeting brings together the biggest names and brightest minds in cancer research, and this year was…
The Top LineForging the future of cell therapy: Bayer and BlueRock’s unique journey (Sponsored)
In this episode of The Top Line, Fierce Biotech’s Chris Hayden sat down with Dr. Juergen Eckhardt of Bayer and Dr. Seth Ettenberg of BlueRock…
The Top LineScience-led storytelling takes center stage in pharma communications (Sponsored)
In the latest episode of The Top Line podcast, host Heath Clendenning interviews Cheryl Lubbert, CEO of Reverba Global, to discuss how science-led storytelling…
The Top LineBiopharma briefing: Q1 trends, gene therapy updates and ASCO preview
Despite the long holiday weekend, news in biopharma never slows down. In this week’s episode of "The Top Line," the Fierce team breaks down some of the…
The Top LineA Fierce breakdown of the 'most favored nation' executive order
President Donald Trump put the pharmaceutical industry on notice early Monday with the signing of his "most favored nation" (MFN) executive order on drug…